参考文献/References:
[1]薄利魁.地西他滨单药五天方案治疗复杂核型骨髓增生异常综合征和急性髓系白血病临床分析[J].健康前沿,2016,23(1):67-68.
[2]Wu L,Li X,Chang C,et al.Efficacy and Toxicity of Decitabine versus CHG Regimen(Low-dose Cytarabine, Homoharringtonine and Granulocyte Colony-stimulating Factor) in Patients with Higher Risk Myelodysplastic Syndrome:a Retrospective Study[J].Leukemia & Lymphoma,2016,57(6):1367-1374.
[3]Gao S,Li Z,Fu JH,et al.Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively[J].Asian Pacific Journal of Cancer Prevention Apjcp,2015,16(15):6627-6632.
[4]Garcia-Manero G,Couriel DR,Tambaro FP,et al.A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS)[J].Blood,2009,114(22):119.
[5]Jabbour EJ,Garciamanero G,Strati P,et al.Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium[J].Cancer,2015,121(6):876-882.
[6]叶丽,任艳玲,谢丽丽,等.小剂量地西他滨治疗较低危骨髓增生异常综合征患者疗效初步观察[J].中华血液学杂志,2017,38(4):307.
[7]Steensma DP,Baer MR,Slack JL,et al.Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial[J].Journal of Clinical Oncology,2009,27(23):3842-3848.
[8]赵龙,席亚明,郭敏,等.小剂量地西他滨治疗中高危骨髓增生异常综合征的Meta分析[J].肿瘤防治研究, 2013,40(5):473-477.
[9]Li X,Song Q,Chen Y,et al.Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis[J].PLoS One,2014,9(4):e95473.
[10]李萨萨,陶千山,蒲莲芳,等.超小剂量地西他滨治疗骨髓增生异常综合征的近期疗效和不良反应观察[J].安徽医药,2016,20(6):1174-1178.
[11]陈亚丽,郭荣,李英梅,等.低剂量地西他滨治疗中高危骨髓增生异常综合征患者38例疗效观察[J].中华实用诊断与治疗杂志,2016,30(6):620-622.
[12]Wei G,Ni W,Chiao J,et al.A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Journal of Hematology & Oncology,2011,4(1):46.
[13]黄达永,付丽,魏娜,等.小剂量地西他滨联合阿糖胞苷治疗骨髓增生异常综合征临床观察[J].白血病·淋巴瘤,2016,25(7):406-408.
[14]高苏,仇惠英,金正明,等.地西他滨单药及联合半程和全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J].中华血液学杂志,2014,35(11):961-965.
[15]Chen W,Zhao W,Yang H,et al.Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome[J].Leukemia Research,2015,39(4):424.
[16]Wu P,Liu L,Weng J,et al.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide (ATO) in the Human Myelodysplastic Syndrome Cell Line SKM-1[J].Indian Journal of Hematology & Blood Transfusion,2016,32(4):412-417.
[17]Adès L,Itzykson R,Fenaux P.Myelodysplastic syndromes[J].Lancet,2014,383(9936):2239-2252.
[18]Traina F,Visconte V,Elson P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia,2014,28(1):78-87.
[19]Wu L,Shi W,Xiao L,et al.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome[J]. Journal of Translational Medicine,2016,14(1):66.
[20]Wang J,Yi Z,Wang S,et al.The effect of decitabine on megakaryocyte maturation and platelet release[J].Thrombosis & Haemostasis,2011,106(2):337-343.
相似文献/References:
[1]沈季敏,刘 欣,吴金菊.骨髓增生异常综合征患者临床特征分析[J].医学信息,2018,31(18):49.[doi:10.3969/j.issn.1006-1959.2018.18.016]
SHEN Ji-min,LIU Xin,WU Jin-ju.Analysis of Clinical Features of Patients with Myelodysplastic Syndrome[J].Journal of Medical Information,2018,31(09):49.[doi:10.3969/j.issn.1006-1959.2018.18.016]
[2]楼 芸,周永明,朱文伟.骨髓间充质干细胞异常在MDS发病机制中的研究[J].医学信息,2020,33(06):24.[doi:10.3969/j.issn.1006-1959.2020.06.008]
LIU Yin,HE Qi-hong,YU Lin-song,et al.Study of Bone Marrow Mesenchymal Stem Cell Abnormalities in the Pathogenesis of MDS[J].Journal of Medical Information,2020,33(09):24.[doi:10.3969/j.issn.1006-1959.2020.06.008]
[3]赵崇山,王宁方.脾脏硬度对初发骨髓增生异常综合征患者预后的影响[J].医学信息,2022,35(07):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]
ZHAO Chong-shan,WANG Ning-fang.Effect of Spleen Stiffness Measurement on Prognosis of Patients with Primary Myelodysplastic Syndrome[J].Journal of Medical Information,2022,35(09):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]
[4]刘华志,王春森.骨髓增生异常综合征突变基因与预后关系的研究现状[J].医学信息,2022,35(02):51.[doi:10.3969/j.issn.1006-1959.2022.02.013]
LIU Hua-zhi,WANG Chun-sen.Research Status of Relationship Between Mutation Gene and Prognosis inMyelodysplastic Syndrome[J].Journal of Medical Information,2022,35(09):51.[doi:10.3969/j.issn.1006-1959.2022.02.013]
[5]汪 梅,李 丽,任咏惠,等.去甲基化药物联合预激方案在骨髓增生异常综合征中的应用[J].医学信息,2022,35(06):41.[doi:10.3969/j.issn.1006-1959.2022.06.010]
WANG Mei,LI Li,REN Yong-hui,et al.Application of Demethylated Drugs Combined with Preexcitation Regimen in Myelodysplastic Syndrome[J].Journal of Medical Information,2022,35(09):41.[doi:10.3969/j.issn.1006-1959.2022.06.010]